Search
Lexaria Bioscience Corp
LEXXAdd to Watchlist
0.560USD
-0.012-2.08%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
13.94MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Lexaria Bioscience Corp is 8.00, ranking 56 out of 157 in the Pharmaceuticals industry. The average price target is 6.00, with a high of 6.00 and a low of 4.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
3.750
Target Price
+555.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
Lexaria Bioscience Corp
LEXX
1
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
AbbVie Inc
ABBV
33
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lexaria Bioscience Corp's expected revenue for the next quarter?
Lexaria Bioscience Corp's expected revenue is 50.00K.
What is Lexaria Bioscience Corp's price target?
Analysts forecast that Lexaria Bioscience Corp's price target is USD 6.00, with the highest forecast at USD 6.00 and the lowest forecast at USD 4.00.
How have Lexaria Bioscience CorpLEXX's recent earnings per share performed?
The market expectation was USD -0.06, while Lexaria Bioscience CorpLEXX's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Lexaria Bioscience Corp?
Based on the ratings of Lexaria Bioscience Corp's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.